- Conditions
- Obesity
- Interventions
- Medically tailored meals, Noom®, Usual care
- Other · Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 177
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Participants
- Interventions
- AZD5004
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Type2 Diabetes, Kidney Diseases
- Interventions
- Exenatide Extended Release for Inj Susp 2 MG, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
- Interventions
- Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • St Louis, Missouri
- Conditions
- Overweight and Obesity, Healthy
- Interventions
- NG101, Placebo, Semaglutide Injectable Product
- Drug
- Lead sponsor
- Neurogastrx, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Type 2 Diabetes, Obesity
- Interventions
- Very Low Calorie Diet
- Other
- Lead sponsor
- Durham VA Medical Center
- Federal
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Overweight or Obesity
- Interventions
- Olatorepatide, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 3
- States / cities
- Walnut Creek, California • Winter Park, Florida • San Antonio, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 28
- States / cities
- Huntington Park, California • Los Angeles, California • Montclair, California + 24 more
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Diabetes Mellitus, Obesity
- Interventions
- PF-07081532, Placebo, Rybelsus
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 39
- States / cities
- Centreville, Alabama • Anaheim, California • Canoga Park, California + 33 more
- Conditions
- Spinal Cord Injuries, Type 2 Diabetes
- Interventions
- Semaglutide Injectable Product, Placebo
- Drug · Other
- Lead sponsor
- Marzieh Salehi
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Children and Adolescent With Type 2 Diabetes
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 16
- States / cities
- Los Angeles, California • New Haven, Connecticut • Iowa City, Iowa + 13 more
- Conditions
- Muscle Mass
- Interventions
- Strength Training, Wait first, then strength training
- Behavioral · Other
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Blacksburg, Virginia
- Conditions
- PCOS, Adolescent Obesity, NAFLD
- Interventions
- Semaglutide 3mg and 7mg [Rybelsus], Weight loss diet
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 21 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia, Metabolic Comorbidities
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 859 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Autosomal Dominant Polycystic Kidney, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Obesity, Diabetes Type 2
- Interventions
- Semaglutide Pen Injector [Ozempic]
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Lancaster, Pennsylvania
- Conditions
- Healthy, Hepatic Insufficiency
- Interventions
- LY3502970
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2 Diabetes
- Interventions
- Diabetes Staging System (DSS) use among Primary Care Teams
- Other
- Lead sponsor
- Durham VA Medical Center
- Federal
- Eligibility
- 25 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
- Interventions
- Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin Glargine, Metformin, Prandial insulin, Exenatide
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 12
- States / cities
- San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- GLP-1 receptor agonist, Insulin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 550,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more